No, Levothyroxine and Lip-Thyroxin Should NOT Be Prescribed Together
Levothyroxine and Lip-thyroxin (which is simply a brand name for levothyroxine) are the same medication and should never be prescribed together. This would result in unintentional overdosing with potentially serious cardiovascular and skeletal consequences.
Understanding the Confusion
Lip-thyroxin is not a separate medication—it is merely a brand or formulation name for levothyroxine sodium. Prescribing both would be equivalent to prescribing two different brands of the same drug simultaneously, leading to:
- Iatrogenic hyperthyroidism with suppressed TSH levels
- Cardiovascular complications including atrial fibrillation (particularly in elderly patients) 1
- Accelerated bone loss in postmenopausal women 1
- Affective disturbances 1
The Risks of Overtreatment
The guidelines explicitly warn that overtreatment with levothyroxine occurs in 20% of treated patients and carries significant morbidity 1. The FDA drug label emphasizes that thyroid hormones should never be used in combination for weight loss or obesity treatment, as larger doses "may produce serious or even life-threatening manifestations of toxicity" 2.
Proper Levothyroxine Management
Use only ONE levothyroxine preparation consistently:
- Current recommendations strongly encourage using a consistent levothyroxine preparation for individual patients to minimize variability 1
- If switching between formulations is necessary (e.g., from tablet to liquid capsule), TSH should be rechecked within 4-8 weeks 1
- The therapeutic endpoint is achieving target TSH levels (typically 0.5-2.5 mIU/L for most patients), not combining multiple preparations 1
Common Pitfall to Avoid
The only scenario where confusion might arise is if a patient is inadvertently filling prescriptions at different pharmacies or if there's a misunderstanding about brand versus generic names. Always verify that patients are taking only one levothyroxine product and instruct them to use the same pharmacy to prevent accidental duplication.
If inadequate TSH control occurs on standard levothyroxine monotherapy, the solution is dose adjustment (typically in 12.5-25 mcg increments) 1, not adding a second levothyroxine product. Patients requiring high doses (>200 mcg/day) with persistently elevated TSH should be evaluated for non-compliance or absorption issues 1, not given additional levothyroxine formulations.